StageZero Life Sciences Ltd. announced that Matthew J. Pietras has been appointed as Chief Operating Officer, effective August 28, 2021. Pietras was most recently Vice President of Finance at CiVi Biopharma. Carl Solomon, StageZero's interim CFO has announced his resignation and will step down August 28, 2021. In addition to leading the finance function, including oversight of accounting, financial reporting analysis and controls, treasury and investor relations, Pietras will head StageZero's operations, including its U.S. lab in Richmond, Virginia. Pietras will be based in Washington D.C., near the U.S. lab, and will report to Chief Executive Officer James R. Howard-Tripp. Pietras brings two decades of financial executive experience, primarily at life science companies. Prior to joining StageZero Life Sciences, he was Vice President of Finance at Maryland-based CiVi Biopharma, where he was responsible for the oversight of Finance and Operations. Prior to that, he was Corporate Treasurer and Controller of Viela Bio from 2017 through 2019. At Viela Bio, the spin-out of AstraZeneca's AutoImmune Franchise, he was responsible for the design and implementation of the financial operations and preparing the company for its eventual IPO. From 2013 through 2017, he held senior finance roles at AstraZeneca/Medimmune, culminating in his position as Global Therapeutic Area Finance Director for the company's Oncology portfolio. He also held finance roles at Wells Fargo, Wachovia, and KPMG.